The approval covers IV and subcutaneous pembrolizumab and raises the TMB-H threshold from 10 to 13 mutations/megabase.

The oral, once-daily EGFR inhibitor is now in specialty distribution for patients whose disease progressed after ...

Erika Hamilton, MD, breaks down liver monitoring, diarrhea, creatinine shifts, and oral adherence with maintenance tucatinib ...

The University of Kansas Cancer Center The University of South Alabama, Mitchell Cancer Institute The University of Texas MD Anderson Cancer Center The Winthrop P. Rockefeller Cancer Institute at the ...

The FDA granted accelerated approval to dostarlimab (Jemperli) on October 19, 2026, for adults with stage II/III locally ...

Rev. Diane Baldwin is manager of Oncology Navigation Programs at the University of South Alabama Mitchell Cancer Institute (MCI) where she is also appointed as Chaplain. She is a member of the Academy ...

Alongside urinary symptoms, the regimen can cause systemic effects such as chills, fever, and musculoskeletal pain. Eppie ...

OncologyLive: Caregiver Connection | Publications | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.

Nogapendekin alfa inbakicept-pmln plus BCG now covers high-grade papillary-only disease, based on extrapolation from CIS ...

Among patients with bacillus Calmette-Guérin (BCG)–unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) who achieved a complete response (CR) with nogapendekin alfa ...

Oral vitamin C at 1000 mg daily for 12 months did not slow clonal growth in adults with clonal cytopenia of undetermined ...

NP Theresa Stukus and NP Nelli Zafman conclude the discussion by reflecting on the resources, practice changes, and ...